Enzyme Kinetics 12 Flashcards

1
Q

Rates of enzyme catalyzed reactions

A
  • enzyme kinetics: used to determine quantitative relationships
  • a progressive curve is used to measure a product formation (or substrate loss) as a function of time
  • velocity is linear at first, but may decrease due to product inhibition as equilibrium is approached, or by enzyme inactivation
  • the rate of product formation will generally increase with the amount of enzyme present (assay)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Rate equations

A

-a unimolecular reaction has a velocity rate that is dependent on the concentration of only one substrate
V=k[A], where the rate constant k has unit sec^-1

-a bimolecular (second order) reaction has a velocity that is dependent on 2 substrat concentrations

V=k[A][B], where k is M^-1 sec^-1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Velocity vs substrate conc

A

Velocity vs [S] curve is hyperbolic

-dependent upon rate determining step

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Michaelis-Menten Equation

A

V=Vmax[S]/Km+[S]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Rate vs efficiency

A

-catalytic rate constant determines how quickly and enzyme can act, while Kcat/Km determines catalytic efficiency
-Kcat = catalytic rate constant/turnover number. The number of catalytic cycles that each active site undergoes per unit time, when the enzyme is saturated with [S]
Kcat=Vmax/[Etotal]
-Kcat often equivalent to K2 (RDS)
-catalytic efficient reflects enzyme rate and substrate affinity
-enzymes reach catalytic perfection when their rate is diffusion controlled (react as quickly as they are available)
Kcat/Km=10^8 or 10^9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lineweaver-Burk ploy

A
  • linearizes the Michaelis-Menten kinetics data

- takes reciprocal of both sides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Reversibility of enzyme inhibition

A
  • enzyme inhibitors are important in medicine and biotechnology, and as research tools
  • irreversible inhibitors usually modify the active site covalently and cannot be reversed
  • Transition state analogs often make better inhibitors than substrate analogs (tighter binding to active site)
  • Reversible inhibitors normally bind to enzymes non-covalently, and can be classified by where they bind and what reaction steps they block; these are kinetically distinguishable:
    • competitive
    • non-competitive
    • uncompetitive
    • mixed etc…
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Competitive Inhibitors

A
  • increase Km
  • substrate and inhibitor bind at same site and are mutually exclusive.
  • large excess of S can overwhelm I
  • Km increased
  • Vmax unchanged
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Non-competitive inhibitors

A
  • decrease Vmax
  • S and I are not mutually exclusive, but ESI complex is less active than ES
  • Km unchanged
  • Vmax decreased
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Other types of inhibition

A

-mixed: similar to non-competitive but binding to stand site modifies Vmax and Km

  • uncompetitive: inhibitors bind to enzyme after substrate binds
    • both Vmax and Km are reduced by same amount
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Exceptions to Michaelis-Menten kinetics

A
  • not all enzymes follow Michael is-men ten kinetics
  • many require multiple substrates/products and/or require multiple steps (Chymotrypsin)

-multistep reactions: Km is a complicated function of many rate constants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Allosteric enzymes

A
  • often have multiple subunits and show cooperativity (interaction among subunits produces signmoidal rather than hyperbolic substrate curves (analogous to Hb vs Mb)
  • allosteric affections may inhibit or activate
  • this often involves and early and/or committed step in a metabolic pathway
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clinical connection: drug design to protein kinases

A
  • protein kinases: a family of >500 proteins involved in signalling pathways (and are drug targets for many diseases)
  • the problem: the active site is very similar for many kinases, making selective drug design difficult
  • the solution: design inhibitors to the allosteric site, which is more unique to each enzyme
How well did you know this?
1
Not at all
2
3
4
5
Perfectly